Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year

Maeve Kelleher, Audrey Dunn-Galvin, Jonathan O'B Hourihane, Deirdre Murray, Linda E Campbell, W H Irwin McLean, Alan D Irvine, Maeve Kelleher, Audrey Dunn-Galvin, Jonathan O'B Hourihane, Deirdre Murray, Linda E Campbell, W H Irwin McLean, Alan D Irvine

Abstract

Background: Loss-of-function mutations in the skin barrier protein filaggrin (FLG) are a major risk for atopic dermatitis (AD). The pathogenic sequence of disturbances in skin barrier function before or during the early development of AD is not fully understood. A more detailed understanding of these events is needed to develop a clearer picture of disease pathogenesis. A robust, noninvasive test to identify babies at high risk of AD would be important in planning early intervention and/or prevention studies.

Objectives: To ascertain whether a noninvasive measurement of skin barrier function at day 2 after birth and at 2 months predicts the development of AD at 1 year. Furthermore, to determine whether increases in transepidermal water loss (TEWL) predate the development of clinical AD.

Methods: A total of 1903 infants were enrolled in the Cork Babies After Scope: Evaluating the Longitudinal Impact Using Neurological and Nutritional Endpoints Birth Cohort study from July 2009 to October 2011. Measurements of TEWL were made at birth (day 2) and at 2 and 6 months. The presence of AD was ascertained at 6 and 12 months, and disease severity was assessed by using the SCORing Atopic Dermatitis clinical tool at 6 months and by using both the SCORing Atopic Dermatitis clinical tool and Nottingham Severity Score at 12 months. A total of 1300 infants were genotyped for FLG mutations.

Results: At 6 months, 18.7% of the children had AD, and at 12 months, 15.53%. In a logistic regression model, day 2 upper quartile TEWL measurement was significantly predictive of AD at 12 months (area under the receiver operating characteristic curve, 0.81; P < .05). Lowest quartile day 2 TEWL was protective against AD at 12 months. An upper quartile 2 month TEWL was also strongly predictive of AD at 12 months (area under the receiver operating characteristic curve, 0.84; P < .05). At both ages, this effect was independent of parental atopy, FLG status, or report of an itchy flexural rash at 2 months. Associations were increased when parental atopy status or child FLG mutation status was added into the linear regression model.

Conclusions: Impairment of skin barrier function at birth and at 2 months precedes clinical AD. In addition to providing important mechanistic insights into disease pathogenesis, these findings have implications for the optimal timing of interventions for the prevention of AD.

Keywords: Infant; TEWL; atopic dermatitis; biomarker; filaggrin; predictor; skin barrier.

Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

References

    1. Johansson S.G., Bieber T., Dahl R., Friedmann P.S., Lanier B.Q., Lockey R.F. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832–836.
    1. Duggan E.M., Sturley J., Fitzgerald A.P., Perry I.J., Hourihane J.O. The 2002–2007 trends of prevalence of asthma, allergic rhinitis and eczema in Irish schoolchildren. Pediatr Allergy Immunol. 2012;23:464–471.
    1. Aberg N., Hesselmar B., Aberg B., Eriksson B. Increase of asthma, allergic rhinitis and eczema in Swedish schoolchildren between 1979 and 1991. Clin Exp Allergy. 1995;25:815–819.
    1. Peat J.K., Berg R.H.V.D., Green W.F., Mellis C.M., Leeder S.R., Wolcock A.J. Changing prevalence of asthma in Australian children. BMJ. 1994;308:1591–1596.
    1. Grundy J., Matthews S., Bateman B., Dean T., Arshad S.H. Rising prevalence of allergy to peanut in children: data from 2 sequential cohorts. J Allergy Clin Immunol. 2002;110:784–789.
    1. Spergel J.M. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin North Am. 2010;30:269–280.
    1. Illi S., von Mutius E., Lau S., Nickel R., Grüber C., Niggemann B. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004;113:925–931.
    1. Sears M.R., Holdway M.D., Flannery E.M., Herbison G.P., Silva P.A. Parental and neonatal risk factors for atopy, airway hyper-responsiveness, and asthma. Arch Dis Child. 1996;75:392–398.
    1. Portelli M.A., Hodge E., Sayers I. Genetic risk factors for the development of allergic disease identified by genome-wide association. Clin Exp Allergy. 2015;45:21–31.
    1. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., Zhao Y., Liao H., Lee S.P. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441–446.
    1. Sandilands A., Sutherland C., Irvine A.D., McLean W.H. Filaggrin in the frontline: role in skin barrier function and disease. J Cell Sci. 2009;122:1285–1294.
    1. McAleer M.A., Irvine A.D. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131:280–291.
    1. Irvine A.D., McLean W.H., Leung D.Y. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365:1315–1327.
    1. Rodríguez E., Baurecht H., Herberich E., Wagenpfeil S., Brown S.J., Cordell H.J. Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. J Allergy Clin Immunol. 2009;123:1361–1370.e7.
    1. Brown S.J., McLean W.H. One remarkable molecule: filaggrin. J Investig Dermatol. 2012;132:751–762.
    1. Nikolovski J., Stamatas G.N., Kollias N., Wiegand B.C. Barrier function and water-holding and transport properties of infant stratum corneum are different from adult and continue to develop through the first year of life. J Investig Dermatol. 2008;128:1728–1736.
    1. Cork M.J., Danby S.G., Vasilopoulos Y., Hadgraft J., Lane M.E., Moustafa M. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129:1892–1908.
    1. Seidenari S., Giusti G. Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol. 1995;75:429–433.
    1. Flohr C., England K., Radulovic S., McLean W.H., Campbell L.E., Barker J. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. Br J Dermatol. 2010;163:1333–1336.
    1. Elias P.M., Hatano Y., Williams M.L. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121:1337–1343.
    1. Strid J., Hourihane J., Kimber I., Callard R., Strobel S. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur J Immunol. 2004;34:2100–2109.
    1. Lack G., Fox D., Northstone K., Golding J. Factors associated with the development of peanut allergy in childhood. N Engl J Med. 2003;348:977–985.
    1. Boralevi F., Hubiche T., Leaute-Labreze C., Saubusse E., Fayon M., Roul S. Epicutaneous aeroallergen sensitization in atopic dermatitis infants—determining the role of epidermal barrier impairment. Allergy. 2008;63:205–210.
    1. Simpson E.L., Berry T.M., Brown P.A., Hanifin J.M. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63:587–593.
    1. Simpson E.L., Chalmers J.R., Hanifin J.M., Thomas K.S., Cork M.J., McLean W.H. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134:818–823.
    1. Horimukai K., Morita K., Narita M., Kondo M., Kitazawa H., Nozaki M. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134:824–830.e6.
    1. AB. MSN. Welcome to the BASELINE study. 2008. Available at: . Accessed June 26, 2013.
    1. SCOPE Consortium and MedSciNet AB. 2004. Available at: . Accessed May 9, 2013.
    1. Williams H.C., Jburney P.G., Pembroke A.C., Hay R.J. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis, III: independent hospital validation. Br J Dermatol. 1994;131:406–416.
    1. Williams H.C., Burney P.G., Hay R.J., Archer C.B., Shipley M.J., Hunter J.J. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis, I: derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131:383–396.
    1. Williams H.C., Burney P.G., Strachan D., Hay R.J. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis, II: observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol. 1994;131:397–405.
    1. Stalder J.F., Taïeb A. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology. 1993;186:23–31.
    1. Kunz B., Oranje A.P., Labrèze L., Stalder J.F., Ring J., Taïeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195:10–19.
    1. Emerson R.M., Charman C.R., Williams H.C. The Nottingham Eczema Severity Score: preliminary refinement of the Rajka and Langeland grading. Br J Dermatol. 2000;142:288–297.
    1. Maldonado G., Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993;138:923–936.
    1. Budtz–Jørgensen E., Keiding N., Grandjean P., Weihe P. Confounder selection in environmental epidemiology: assessment of health effects of prenatal mercury exposure. Ann Epidemiol. 2007;17:27–35.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться